Table 3. The effect of BM-MSCs on plasma fibrinogen concentration (milligrams per deciliter).
| GROUPS (n=10) | Plasma fibrinogen concentration (mg/dL) |
|---|---|
| Normal control | 122.62±2.3 |
| CCl4 trt | 87.45±1.6x |
| Low dose BM-MSCs trt | 95.06±2.7xxa |
| High dose BM-MScs trt | 106.46±2.7xxa |
| Silymarin trt | 93.43±1.6xxa |
| BM-MSCs + silymarin trt | 110.16±1.7xx |
Values expressed as mean ± SD. Post hoc Tukey’s test indicated significant difference between: x, normal control vs. CCl4 trt (P<0.001); xx, CCl4 trt vs. treatment (P<0.001); a, BM-MSCs + silymarin trt vs. other treatments (P<0.001). BM-MSCs, bone marrow-derived mesenchymal stromal cells; CCl4, carbon tetrachloride; SD, standard deviation.